"Table 2- Different vaccine strategies tested in primates and HumansPROPHYL ACTIC/TH IMMUNOGE STAGE OF CURRENTAPPROACH REFERENCE RESULTSERAPEUTI N-ADJUENT DEVELOPMENT STATUSCPeptides/ Prophylac sterilising immunity was E1E2ChimpanzeesPublished[16]proteins tic shownImmunogenic, safe and wellCore-Phase I(30 volunteers) Published[29] tolerated in a group of male,is comat r ix™healthy volunteersE1E2- later studies discontinuedPhase I(60 volunteers) Published[18]MF59C.1due to technical difficultiesE1E2Phase I(50 volunteers) RecruitingNCT01718834 status unknownPhase I/II (128 safe, well tolerated, doseTherapeut IC41-poly-L- volunteers/60 Published[30]dependent immuneic argininepatients) response[31]decline in HCV RNA in serumIC41- IC41 induced immunologicalPhase II (50 patients) Published[32]imiquimod responsePhase II(71 patients) CompletedNCT00601770 no results postedProphylac HCV-LPCore E1E2Chimpanzees Published [33] No trials in humanstic Half of the patients showedTherapeut Core E1E2DNA vector Phase II (15 patients) Published[34] reduction in fibrosis butic(CIGB-230)verimia persistedNS3/4A(Chr Phase IIRecruitingNCT01335711 no results postedonVac-C)Prophylac Ad6NSmutViral vector ChimpanzeesPublished[35]protective effecttic DNA-NsmutAd6NSmut Induced T cell response butChAd3NSmu Phase I (40 volunteers) Published[36]was not effective due to hight cross reactive antibodiesAdCh3NSmu Phase I/II(68 + 276t MVA- RecruitingNCT01436357 RecruitingIDU)NsmutAdCh3NSmu Therapeut Phase I(19 volunteerst MVA- RecruitingNCT01296451 Recruitingic/14 patients)NsmutTG4040Phase I(15 patients) Published[28]decline in viral loadTG4040 + Phase II (153 patients) CompletedNCT01055821 no results postedSOCAd6NSmutChAd3NSmu Phase I (32 patients) CompletedNCT01094873 no results postedtReferences1. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, FrielTJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, KurtzLA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. Evaluation of a new, rapidtest for detecting HCV infection, suitable for use with blood or oral fluid. J VirolMethods 2011; 172: 27-31.2. Scott JD, McMahon BJ, Bruden D, Sullivan D, Homan C, Christensen C, Gretch DR.High rate of spontaneous negativity for hepatitis C virus RNA after establishment ofchronic infection in Alaska Natives. Clin Infect Dis 2006; 42: 945-952.3. Chevaliez S, Pawlotsky JM. How to use virological tools foroptimal management ofchronic hepatitis C. Liver Int 2009; 29 Suppl 1: 9-14. 4. Stuyver, L., A. Wyseur, W. van Arnhem, F. Hernandez, and G. Maertens. (1996)Second-generation line Probe assay for hepatitis C virus genotyping. J. Clin.Microbiol. 34:2259–2266.5. Oliveira ML, Bastos FI, Sabino RR, Paetzold U, Schreier E, Pauli G, Yoshida CF.Distribution of HCV genotypes among different exposure categories in Brazil. Braz JMed Biol Res 1999; 32: 279-282.6. Villar LM, Amado LA, de Almeida AJ, de Paula VS, LewisXimenez LL, Lampe E.Low prevalence of hepatitis B and C virus markers among children and adolescents.Biomed Res Int 2014; 2014: 324638.7. Mondelli, M.U. and Silini, E. (1999) Clinical significance of hepatitis C virusgenotypes. J. Hepatol. 31:6570.8. Raymond HW, Cimmins C. Evaluation of the Abbott Molecular Diagnostics RealTime PCR Assay for HCV Quantitative Viral Load and HCV Genotyping. Poster S30,Clinical Virology Symposium, 2004.9. EASL Recommendations on Treatment of Hepatitis C 2015 Journal of Hepatology2015 vol. 63 199–236. 10. Llinàs-Brunet M, Bailey M, Fazal G, et al. Peptide-based inhibitors of the hepatitis Cvirus serine protease. Bioorg Med Chem Lett 1998;8(13):1713–1718.11. Steinkühler C, Biasiol G, Brunetti M, et al. Product inhibition of the hepatitis C virusNS3 protease. Biochemistry 1998;37(25):8899–8905.12. Abian O, Vega S, Sancho J, Velazquez-Campoy A. Allosteric inhibitors of the NS3protease from the hepatitis C virus. PloS ONE 2013;8(7):e69773.13. Yang W, Sun Y, Hou X, et al. ACH-806, an NS4A antagonist, inhibits hepatitis Cvirus replication by altering the composition of viral replication complexes.Antimicrob Agents Chemother 2013; 57(7):3168–3177.14. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identi?es an HCVNS5A inhibitor with a potent clinical effect. Nature 2010;465(7294):96–100.15. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, DeFrancesco R. HepatitisC virus-speci?c directly acting antiviral drugs. Curr Top Microbiol Immunol2013;369:289–320.16. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K,Thudium K, Kuo C et al: Vaccination of chimpanzees against infection by thehepatitis C virus. Proceedings of the National Academy of Sciences of the UnitedStates of America 1994, 91(4):1294-1298.17. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, PurcellRH: Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitisC virus. The Journal of infectious diseases 2011, 204(8):1186-1190. 18. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, DiBisceglie AM, Rinella P et al: Safety and immunogenicity of HCV E1E2 vaccineadjuvanted with MF59 administered to healthy adults. Vaccine 2010, 28(38):6367- 6373.19. Huang XJ, Lü X, Lei YF, Yang J, Yao M, Lan HY, Zhang JM, Jia ZS, Yin W, XuZK. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based onhepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice. J Virol Methods2013; 189: 47-52.20. Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, RahimniaR, Alavian SM, Rafati S, Samimi Rad K: Immunogenicity of Multi-Epitope DNA andPeptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes inBALB/c Mice. Hepatitis monthly 2014, 14(10):e22215.21. Chong SY, Egan MA, Kut zl er MA, Megat i S, Masood A, Roopchard V, Garcia- Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN,Weiner DB, Sidhu M, Eldridge JH, Israel ZR. Comparative ability of plasmid IL-12and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgagplasmid DNA vaccine and alter disease progression following SHIV(89.6P) challengein rhesus macaques. Vaccine 2007; 25: 4967-4982. 22. Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, ParkinsonR, Wu L, Sidhu MK, Pavlakis GN, Felber BK, Brown C, Silvera P, Lewis MG,Monforte J, Waldmann TA, Eldridge J, Weiner DB. Protection against simian/humani mmu n o d e f i c i e n c y v i r u s ( S HI V) 8 9 . 6 P i n ma c a q u e s a f t e rcoimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci USA2007; 104: 18648-18653.23. Naderi M, Gholipour N, Zolfaghari MR, Moradi Binabaj M, Yegane Moghadam A,Motalleb G. Hepatitis C virus and vaccine development. Int J Mol Cell Med 2014; 3:207-215.24. Sallberg MM, Frelin L, Diepolder H. A first clinical trial of therapeutic vaccinationusing naked DNA delivered by in vivo electroporation shows antiviral effects inpatients with chronic hepatitis C. J Hepatol 2009; 50: S18-S19.25. Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, VerhoyeL, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux- Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.Combined adenovirus vector and hepatitis C virus envelope protein prime-boostregimen elicits T cell and neutralizing antibody immune responses. J Virol 2014; 88:5502-5510.26. Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strainMVA: marker, genetic structure, experience gained with the parenteral vaccinationand behavior in organisms with a debilitated defence mechanism (author’s transl)].Zentralbl Bakteriol B 1978; 167: 375-390. 27. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinantgenes. Proc Natl Acad Sci USA 1992; 89: 10847-10851. 28. Habersetzer F, Zarski JP, Leroy V, aynard-Muet M, Bronowicki JP, Feray C, HézodeC, Fournillier A, Bain C, Inchauspé G, Honnet G, Trépo C. A novel vectorized HCVtherapeutic vaccine (TG4040): Results of a phase I study in naive patients chronicallyinfected by HCV. J Hepatol 2009; 50: S18.29. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D,Gervase B, Coates S, Houghton M, Basser R. Priming of CD4+ and CD8+ T cellresponses using a HCV core ISCOMATRIX vaccine: a phase I study in healthyvolunteers. HumVaccin 2009; 5: 151-157. 30. Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K,Buschle M, Frisch J,Klade CS. Immunogenicity and safety ofa novel therapeutic hepatitis C virus (HCV)peptide vaccine: arandomized, placebo controlled trial for dose optimization in128healthy subjects. Vaccine 2006; 24: 4343-4353. 31. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H,Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP. Therapeuticvaccination of chronic hepatitis C nonresponder patients with the peptide vaccineIC41. Gastroenterology 2008; 134: 1385-1395. 32. Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP. Sustained viral loadreduction in treatment-naive HCV genotype 1 infected patients after therapeuticpeptide vaccination. Vaccine 2012; 30: 2943-2950.33. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, MurthyK, Liang TJ. Immunization with hepatitis C virus-like particles results in control ofhepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104: 8427- 8432.34. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N,Guerra I, Drouin C, Dubuisson J, GonzálezHorta EE, Martínez G, Marante J, Cinza Z,Castellanos M, Dueñas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNAvaccine preparation, in HCV-chronically infected individuals in a Phase I clinicaltrial. J Viral Hepat 2009; 16: 156-167. 35. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB,Pezzanera M, TafiR, Arcuri M, Fattori E, Lahm A, Luzzago A,Vitelli A, Colloca S, Cortese R, NicosiaA. A T-cell HCV vaccineeliciting effective immunity against heterologous viruschallenge in chimpanzees. Nat Med 2006; 12: 190-197. 36. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, HuddartR, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O’HaraG, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y,Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. Noveladenovirusbased vaccines induce broad and sustained T cell responses to HCV inman. Sci Transl Med 2012; 4: 115. "